Establishment of preclinical mechanistic in vitro-in vivo correlations for long-acting injectable suspensions​

Establishment of preclinical mechanistic in vitro-in vivo correlations for long-acting injectable suspensions​

Conference: AAPS
Division: PBPK

Long acting injectable (LAI) formulations administered through subcutaneous (SC) or intramuscular (IM) routes provide sustained drug release over an extended period.

Use of Quantitative Systems Toxicology (QST) to Identify Potential Intrinsic Mechanisms of Toxicity

Use of Quantitative Systems Toxicology (QST) to Identify Potential Intrinsic Mechanisms of Toxicity

Conference: AAPS
Software: DILIsym®

BAY1128688, a selective inhibitor of aldo-keto reductase family 1 member C3 (AKR1C3), was in clinical trials as a potential therapy to provide pain relief for women with endometriosis.

Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model

Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model

Publication: Xenobiotica
Software: GastroPlus®
Division: PBPK

Prediction of rat, dog, monkey, and human volume of distribution (VDss) by Rodgers-Lukacova model was evaluated using a data set of more than 100 compounds.

In vitro antibacterial activity and in vivo pharmacokinetics of intravenously administered Amikacin-loaded Liposomes for the management of bacterial septicaemia

In vitro antibacterial activity and in vivo pharmacokinetics of intravenously administered Amikacin-loaded Liposomes for the management of bacterial septicaemia

Publication: Colloids Surf B Biointerfaces
Software: GastroPlus®

Systemic delivery of amikacin is a widely adopted treatment modality for severe infections like sepsis. However, the current course of treatment requires repeated bolus doses of amikacin, prolonged hospitalization, and continuous therapeutic monitoring to manage the severe adverse effects.

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

Publication: CPT Pharmacometrics Syst Pharmacol

The analysis aimed at identifying subject-specific characteristics (covariates) influ-encing exposure to daridorexant and quantification of covariate effects to determineclinical relevance.

Pimavanserin exposure–response analyses in patients with schizophrenia: results from the phase 2 ADVANCE study

Pimavanserin exposure–response analyses in patients with schizophrenia: results from the phase 2 ADVANCE study

Publication: Journal of Clinical Psychopharmacology

Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist/antagonist being investigated in patients with negative symptoms of schizophrenia. This analysis aimed to characterize exposure-response relationships of...

Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study

Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study

Publication: Clin Transl Sci
Software: GastroPlus®

In vitro-in vivo correlation (IVIVC) allows prediction of the in vivo performance of a pharmaceutical product based on its in vitro drug release profiles...